BHCM
CTMX icon

Brevan Howard Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Brevan Howard Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-269,202
Closed -$1.27M – 2164
2026
Q1 		$1.27M Buy
269,202
+257,798
+2,261% +$1.31M 0.01% 782
2025
Q4 		$48.6K Buy
+11,404
New +$43.3K ﹤0.01% 1700
2024
Q2 		– Sell
-18,056
Closed -$39.4K – 1115
2024
Q1 		$39.4K Buy
+18,056
New +$33.3K ﹤0.01% 947

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Brevan Howard Capital Management's CTMX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 269,202 shares — an estimated $1.27M sold.

Brevan Howard Capital Management first reported a position in CTMX in Q1 2024 and held it in 3 quarters. The position peaked at $1.27M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 269,202 CytomX Therapeutics shares in Q2 2026, an estimated $1.27M.
  • Brevan Howard Capital Management first reported a position in CytomX Therapeutics in Q1 2024 and held it in 3 quarters.
  • Brevan Howard Capital Management's CytomX Therapeutics position peaked at $1.27M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.